[Depakene (sodium valproate) in the treatment of epilepsy in children and adolescents: efficiency and safety].

Abstract

375 patients 7 months-19 years of age with different forms of epilepsy were treated with depakine. High efficiency of the drug was found in all forms of children's epilepsy. A complete remission was observed in 60% of the patients, a good effect--in 19%, a satisfactory effect--in 15%, 6%--were non-responders. The highest efficiency of depakine was achieved in idiopathic forms of epilepsy (complete remission--in 74% of the cases) and, therefore, depakine can be used as a monotherapy. Meanwhile, the efficiency of depakine was lower in cryptogenic generalized and symptomatic partial epilepsy. In such cases depakine should be used as a basic preparation in polytherapy. Side effects were observed in 35% of the cases, but stopping of therapy was necessary only in 25% of such cases. Rare idiosyncrasy and no negative influence on the cognitive functions were important-properties of depakine.

• Authors: A S Petrukhin, K Iu Mukhin
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 101 Issue 6 Pg. 20-7 ( 2001) ISSN: 1997-7298 [Print] Russia (Federation)
• Vernacular Title: Depakin (val'proat natriia) v lechenii épilepsii u deteĭ i podrostkov: éffektivnost' i perenosimost'.
• PMID: 11517881 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anticonvulsants
• Valproic Acid

Topics

• Adolescent
• Adult
• Anticonvulsants (administration & dosage, adverse effects, therapeutic use)
• Child
• Child, Preschool
• Drug Administration Schedule
• Epilepsy (drug therapy)
• Female
• Humans
• Infant
• Male
• Treatment Outcome
• Valproic Acid (administration & dosage, adverse effects, therapeutic use)